Published in Cochrane Database Syst Rev on July 08, 2009
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology (2010) 2.32
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol (2010) 1.80
Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol (2011) 1.35
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One (2013) 1.20
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist (2013) 1.19
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res (2011) 1.03
A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis (2012) 1.02
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med (2013) 1.02
Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist (2011) 1.00
Dual targeting of insulin and venus kinase Receptors of Schistosoma mansoni for novel anti-schistosome therapy. PLoS Negl Trop Dis (2013) 1.00
Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. World J Gastroenterol (2014) 0.98
Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels. Circ Res (2011) 0.97
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis (2011) 0.94
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer (2013) 0.93
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs (2009) 0.90
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett (2011) 0.84
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer (2013) 0.83
Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Neoplasia (2014) 0.82
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist (2010) 0.81
Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study. J Transl Med (2015) 0.81
Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis (2011) 0.81
Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol (2013) 0.80
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol (2013) 0.80
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther (2012) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report. J Med Case Rep (2012) 0.78
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2016) 0.77
Neovascularization in tissue engineering. Cells (2012) 0.77
Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis. Korean J Hepatol (2010) 0.76
A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol (2012) 0.76
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. Oncol Ther (2016) 0.75
Meta-regression of treatments for metastatic colorectal cancer: Quantifying incremental benefit from 2000 to 2012. World J Clin Oncol (2014) 0.75
Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease. Int Sch Res Notices (2015) 0.75
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Int J Clin Oncol (2016) 0.75
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol (2012) 5.86
Cohort profile: the study of health in Pomerania. Int J Epidemiol (2010) 4.38
Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (2010) 3.67
Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery (2004) 2.18
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med (2010) 1.84
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. J Clin Oncol (2009) 1.66
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol (2008) 1.65
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.58
Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg (2005) 1.53
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie (2007) 1.46
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol (2007) 1.43
Transcoronary pacing in a porcine model--impact of guidewire insulation. J Invasive Cardiol (2011) 1.42
Skeletal muscle metastases: primary tumours, prevalence, and radiological features. Eur Radiol (2009) 1.38
Cumulative occupational lumbar load and lumbar disc disease--results of a German multi-center case-control study (EPILIFT). BMC Musculoskelet Disord (2009) 1.36
Cardiovascular disease, risk factors and heart rate variability in the elderly general population: design and objectives of the CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. BMC Cardiovasc Disord (2005) 1.33
Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int (2009) 1.25
Cardiovascular diseases, risk factors and short-term heart rate variability in an elderly general population: the CARLA study 2002-2006. Eur J Epidemiol (2009) 1.22
Prevention and health promotion in undergraduate medical education: Preferences, attitudes and previous knowledge of medical students - a cross-sectional study. GMS Z Med Ausbild (2011) 1.18
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev (2012) 1.12
Port catheter insufficiency: incidence and clinical-radiological correlations. Onkologie (2008) 1.11
Breast plasmacytoma. Acta Radiol (2010) 1.08
Association of childhood and adult socioeconomic indicators with cardiovascular risk factors and its modification by age: the CARLA Study 2002-2006. BMC Public Health (2011) 0.98
Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One (2013) 0.97
A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer (2013) 0.96
Oxaliplatin: a review of approved uses. Expert Opin Pharmacother (2012) 0.95
Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys (2010) 0.95
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev (2015) 0.95
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev (2011) 0.94
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res (2011) 0.92
Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer (2010) 0.92
Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int (2011) 0.92
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol (2013) 0.91
Association of occupation with prevalent hypertension in an elderly East German population: an exploratory cross-sectional analysis. Int Arch Occup Environ Health (2010) 0.90
Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep (2011) 0.90
Intramuscular manifestation of non-Hodgkin lymphoma and myeloma: prevalence, clinical signs, and computed tomography features. Acta Radiol (2010) 0.89
Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer (2010) 0.89
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther (2014) 0.88
Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging. PLoS One (2012) 0.88
Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res (2011) 0.87
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol (2014) 0.86
[Motivation and barriers to participation in clinical trials]. Med Klin (Munich) (2006) 0.86
Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol (2012) 0.85
Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat (2015) 0.84
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev (2014) 0.84
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest (2010) 0.84
Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys (2013) 0.83
Evolutionary aspects and muscular properties of the trunk--implications for human low back pain. Pathophysiology (2005) 0.83
Lifestyle factors and lumbar disc disease: results of a German multi-center case-control study (EPILIFT). Arthritis Res Ther (2010) 0.83
Laryngeal pacing in minipigs: in vivo test of a new minimal invasive transcricoidal electrode insertion method for functional electrical stimulation of the PCA. Eur Arch Otorhinolaryngol (2012) 0.83
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. Acta Oncol (2013) 0.82
Time domain parameters can be estimated with less statistical error than frequency domain parameters in the analysis of heart rate variability. J Electrocardiol (2008) 0.82
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study. Radiat Oncol (2012) 0.82
PTEN deletion is rare but often homogeneous in gastric cancer. J Clin Pathol (2012) 0.81
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer (2012) 0.81
Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial? Strahlenther Onkol (2010) 0.81
Physical workload and accelerated occurrence of lumbar spine diseases: risk and rate advancement periods in a German multicenter case-control study. Scand J Work Environ Health (2010) 0.80
Kinematic and electromyographic tools for characterizing movement disorders in mice. Mov Disord (2010) 0.80
A surface EMG multi-electrode technique for characterizing muscle activation patterns in mice during treadmill locomotion. J Neurosci Methods (2005) 0.80
Update on capecitabine in colorectal cancer. Oncologist (2006) 0.80
[Treatment of rectal cancer]. Onkologie (2010) 0.80
Prevalence and Incidence of Hypertension in the General Adult Population: Results of the CARLA-Cohort Study. Medicine (Baltimore) (2015) 0.80
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. Acta Oncol (2014) 0.79
Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases. Acta Radiol (2012) 0.79
Central venous catheter complications during home parenteral nutrition: a prospective pilot study of 481 patients with more than 30,000 catheter days. Onkologie (2008) 0.79
Temporary trans-coronary pacing by coated guidewires: a safe and reliable method during percutaneous coronary intervention. Clin Res Cardiol (2006) 0.78
Association of health behaviour with heart rate variability: a population-based study. BMC Cardiovasc Disord (2010) 0.78
Challenges in the multidisciplinary management of stage IV colon and rectal cancer. Expert Rev Gastroenterol Hepatol (2014) 0.78
[Motivation of patients to participate in clinical trials. An explorative survey]. Med Klin (Munich) (2010) 0.78
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer (2012) 0.78
A novel approach for transcoronary pacing in a porcine model. J Invasive Cardiol (2012) 0.78
Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases. Anticancer Drugs (2002) 0.77
Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. Cancer Biomark (2012) 0.77
Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. Onkologie (2005) 0.77
Treadmill locomotion in normal mice-Step related multi-channel EMG profiles of thigh muscles. Pathophysiology (2006) 0.77
Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. Ann Surg Oncol (2013) 0.77
Diurnal variation in the renal excretion of modified RNA catabolites in humans. Clin Sci (Lond) (2003) 0.77
[Adjuvant therapy in colon cancer]. Onkologie (2010) 0.77
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemother Pharmacol (2011) 0.76
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer (2014) 0.76
Association of Change of Anthropometric Measurements With Incident Type 2 Diabetes Mellitus: A Pooled Analysis of the Prospective Population-Based CARLA and SHIP Cohort Studies. Medicine (Baltimore) (2015) 0.76
Fractionated breath condensate sampling: H(2)O(2) concentrations of the alveolar fraction may be related to asthma control in children. Respir Res (2012) 0.76
Aerobic endurance training versus relaxation training in patients with migraine (ARMIG): study protocol for a randomized controlled trial. Trials (2012) 0.76
Thyroid analytes TSH, FT3 and FT4 in serum of healthy elderly subjects as measured by the Roche modular system: do we need age and gender dependent reference levels? Clin Lab (2014) 0.76
Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. Oncology (2016) 0.75
Gene-expression signatures in breast cancer. N Engl J Med (2003) 0.75
The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol (2010) 0.75
Crucial characteristics. Dtsch Arztebl Int (2011) 0.75
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. BMC Cancer (2013) 0.75
Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther Adv Med Oncol (2010) 0.75
Medium-dose prednisolone pulse therapy in alopecia areata. Dermatoendocrinol (2009) 0.75